Literature DB >> 16198049

Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles.

Ivan H El-Sayed1, Xiaohua Huang, Mostafa A El-Sayed.   

Abstract

Efficient conversion of strongly absorbed light by plasmonic gold nanoparticles to heat energy and their easy bioconjugation suggest their use as selective photothermal agents in molecular cancer cell targeting. Two oral squamous carcinoma cell lines (HSC 313 and HOC 3 Clone 8) and one benign epithelial cell line (HaCaT) were incubated with anti-epithelial growth factor receptor (EGFR) antibody conjugated gold nanoparticles and then exposed to continuous visible argon ion laser at 514nm. It is found that the malignant cells require less than half the laser energy to be killed than the benign cells after incubation with anti-EGFR antibody conjugated Au nanoparticles. No photothermal destruction is observed for all types of cells in the absence of nanoparticles at four times energy required to kill the malignant cells with anti-EGFR/Au conjugates bonded. Au nanoparticles thus offer a novel class of selective photothermal agents using a CW laser at low powers. The potential of using this selective technique in molecularly targeted photothermal therapy in vivo is discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16198049     DOI: 10.1016/j.canlet.2005.07.035

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  236 in total

Review 1.  Review of the progress toward achieving heat confinement-the holy grail of photothermal therapy.

Authors:  Wangzhong Sheng; Sha He; William J Seare; Adah Almutairi
Journal:  J Biomed Opt       Date:  2017-08-01       Impact factor: 3.170

2.  Duplex end breathing determines serum stability and intracellular potency of siRNA-Au NPs.

Authors:  Pinal C Patel; Liangliang Hao; Weng Si Au Yeung; Chad A Mirkin
Journal:  Mol Pharm       Date:  2011-06-28       Impact factor: 4.939

Review 3.  Responsive theranostic systems: integration of diagnostic imaging agents and responsive controlled release drug delivery carriers.

Authors:  Mary E Caldorera-Moore; William B Liechty; Nicholas A Peppas
Journal:  Acc Chem Res       Date:  2011-09-20       Impact factor: 22.384

4.  Multidentate-protected colloidal gold nanocrystals: pH control of cooperative precipitation and surface layer shedding.

Authors:  Brad A Kairdolf; Shuming Nie
Journal:  J Am Chem Soc       Date:  2011-04-27       Impact factor: 15.419

5.  Gold nanostar synthesis with a silver seed mediated growth method.

Authors:  Zurab Kereselidze; Victor H Romero; Xomalin G Peralta; Fidel Santamaria
Journal:  J Vis Exp       Date:  2012-01-15       Impact factor: 1.355

Review 6.  Development of mesoporous silica nanomaterials as a vehicle for anticancer drug delivery.

Authors:  Rolando E Yanes; Fuyuhiko Tamanoi
Journal:  Ther Deliv       Date:  2012-03

Review 7.  Development and applications of photo-triggered theranostic agents.

Authors:  Prakash Rai; Srivalleesha Mallidi; Xiang Zheng; Ramtin Rahmanzadeh; Youssef Mir; Stefan Elrington; Ahmat Khurshid; Tayyaba Hasan
Journal:  Adv Drug Deliv Rev       Date:  2010-09-19       Impact factor: 15.470

Review 8.  Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by Fluorescence.

Authors:  Alyssa B Chinen; Chenxia M Guan; Jennifer R Ferrer; Stacey N Barnaby; Timothy J Merkel; Chad A Mirkin
Journal:  Chem Rev       Date:  2015-08-27       Impact factor: 60.622

9.  Chemosensitization of cancer cells via gold nanoparticle-induced cell cycle regulation.

Authors:  Megan A Mackey; Mostafa A El-Sayed
Journal:  Photochem Photobiol       Date:  2014-02-11       Impact factor: 3.421

10.  Engineering of hetero-functional gold nanorods for the in vivo molecular targeting of breast cancer cells.

Authors:  Mohammad Eghtedari; Anton V Liopo; John A Copland; Alexander A Oraevsky; Massoud Motamedi
Journal:  Nano Lett       Date:  2009-01       Impact factor: 11.189

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.